Literature DB >> 17474035

Exposure-response analysis for beryllium sensitization and chronic beryllium disease among workers in a beryllium metal machining plant.

Amy K Madl1, Ken Unice, Jay L Brown, Marc E Kolanz, Michael S Kent.   

Abstract

The current occupational exposure limit (OEL) for beryllium has been in place for more than 50 years and was believed to be protective against chronic beryllium disease (CBD) until studies in the 1990s identified beryllium sensitization (BeS) and subclinical CBD in the absence of physical symptoms. Inconsistent sampling and exposure assessment methodologies have often prevented the characterization of a clear exposure-response relationship for BeS and CBD. Industrial hygiene (3831 personal lapel and 616 general area samples) and health surveillance data from a beryllium machining facility provided an opportunity to reconstruct worker exposures prior to the ascertainment of BeS or the diagnosis of CBD. Airborne beryllium concentrations for different job titles were evaluated, historical trends of beryllium levels were compared for pre- and postengineering control measures, and mean and upper bound exposure estimates were developed for workers identified as beryllium sensitized or diagnosed with subclinical or clinical CBD. Five approaches were used to reconstruct historical exposures of each worker: industrial hygiene data were pooled by year, job title, era of engineering controls, and the complete work history (lifetime weighted average) prior to diagnosis. Results showed that exposure metrics based on shorter averaging times (i.e., year vs. complete work history) better represented the upper bound worker exposures that could have contributed to the development of BeS or CBD. Results showed that beryllium-sensitized and CBD workers were exposed to beryllium concentrations greater than 0.2 microg/m3 (95th percentile), and 90% were exposed to concentrations greater than 0.4 microg/m3 (95th percentile) within a given year of their work history. Based on this analysis, BeS and CBD generally occurred as a result of exposures greater than 0.4 microg/m3 and maintaining exposures below 0.2 microg/m3 95% of the time may prevent BeS and CBD in the workplace.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17474035     DOI: 10.1080/15459620701354747

Source DB:  PubMed          Journal:  J Occup Environ Hyg        ISSN: 1545-9624            Impact factor:   2.155


  7 in total

1.  Beryllium's public relations problem: protecting workers when there is no safe exposure level.

Authors:  David Michaels; Celeste Monforton
Journal:  Public Health Rep       Date:  2008 Jan-Feb       Impact factor: 2.792

2.  Beryllium history and public policy.

Authors:  Marc Kolanz
Journal:  Public Health Rep       Date:  2008 Jul-Aug       Impact factor: 2.792

3.  Beryllium in urine by ICP-MS: a comparison of low level exposed workers and unexposed persons.

Authors:  Jackie Morton; Elizabeth Leese; Richard Cotton; Nicholas Warren; John Cocker
Journal:  Int Arch Occup Environ Health       Date:  2010-10-21       Impact factor: 3.015

4.  Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers.

Authors:  Mike V Van Dyke; John W Martyny; Margaret M Mroz; Lori J Silveira; Matt Strand; Tasha E Fingerlin; Hiroe Sato; Lee S Newman; Lisa A Maier
Journal:  Am J Respir Crit Care Med       Date:  2011-03-11       Impact factor: 21.405

5.  The uses and adverse effects of beryllium on health.

Authors:  Ross G Cooper; Adrian P Harrison
Journal:  Indian J Occup Environ Med       Date:  2009-08

6.  Identifying natural and anthropogenic sources of metals in urban and rural soils using GIS-based data, PCA, and spatial interpolation.

Authors:  Harley T Davis; C Marjorie Aelion; Suzanne McDermott; Andrew B Lawson
Journal:  Environ Pollut       Date:  2009-04-10       Impact factor: 8.071

7.  Associations of Metrics of Peak Inhalation Exposure and Skin Exposure Indices With Beryllium Sensitization at a Beryllium Manufacturing Facility.

Authors:  M Abbas Virji; Christine R Schuler; Jean Cox-Ganser; Marcia L Stanton; Michael S Kent; Kathleen Kreiss; Aleksandr B Stefaniak
Journal:  Ann Work Expo Health       Date:  2019-10-11       Impact factor: 2.179

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.